中成药临床综合评价技术规范(2021)

2021-11-29 中国中医科学院中医临床基础医学研究所 世界中医药

药品临床综合评价为药品上市后临床定位、资源配置、医保与基药准入等工作提供了 有效的依据。中成药临床综合评价除了满足一般药品综合评价 6 个维度外,还应考虑中医药 特色。

中文标题:

中成药临床综合评价技术规范(2021)

发布日期:

2021-11-29

简要介绍:

药品临床综合评价为药品上市后临床定位、资源配置、医保与基药准入等工作提供了 有效的依据。中成药临床综合评价除了满足一般药品综合评价 6 个维度外,还应考虑中医药 特色。目前对于中成药临床综合评价研究的具体实施环节和评价方法比较模糊,因此制定中 成药临床综合评价技术规范迫在眉睫。起草组遵循《中国药品综合评价指南参考大纲(第二 版)》以及《药品临床综合评价管理指南(2021 年版试行)》等文件的相关法规要求,经过文献 复习和专家讨论论证,结合多项中成药临床综合评价研究的实践经验,制定了中成药临床综合 评价技术规范。本规范包括了中成药临床综合评价的临床定位、资料获取、质量控制、评价 内容与方式、各维度的评价技术方法等方面,为中成药开展临床综合评价工作提供方法学指导,使评价过程及结果更加科学合理。

相关资料下载:
[AttachmentFileName(sort=1, fileName=_中成药临床综合评价技术规范.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3d9fb1c0022e701a, title=中成药临床综合评价技术规范(2021), enTitle=, guiderFrom=世界中医药, authorId=0, author=, summary=药品临床综合评价为药品上市后临床定位、资源配置、医保与基药准入等工作提供了 有效的依据。中成药临床综合评价除了满足一般药品综合评价 6 个维度外,还应考虑中医药 特色。, cover=https://img.medsci.cn/Random/130226224201-ac-mediterranean-diet-dr-gupta-00001017-story-body.jpg, journalId=0, articlesId=null, associationId=2171, associationName=中国中医科学院中医临床基础医学研究所, associationIntro=中国中医科学院中医临床基础医学研究所, copyright=0, guiderPublishedTime=Mon Nov 29 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="page" title="Page 2"> <div class="layoutArea"> <div class="column"> <p>药品临床综合评价为药品上市后临床定位、资源配置、医保与基药准入等工作提供了 有效的依据。中成药临床综合评价除了满足一般药品综合评价 6 个维度外,还应考虑中医药 特色。目前对于中成药临床综合评价研究的具体实施环节和评价方法比较模糊,因此制定中 成药临床综合评价技术规范迫在眉睫。起草组遵循《中国药品综合评价指南参考大纲(第二 版)》以及《药品临床综合评价管理指南(2021 年版试行)》等文件的相关法规要求,经过文献 复习和专家讨论论证,结合多项中成药临床综合评价研究的实践经验,制定了中成药临床综合 评价技术规范。本规范包括了中成药临床综合评价的临床定位、资料获取、质量控制、评价 内容与方式、各维度的评价技术方法等方面,为中成药开展临床综合评价工作提供方法学指导,使评价过程及结果更加科学合理。</p> </div> </div> </div>, tagList=[TagDto(tagId=7570, tagName=中成药)], categoryList=[CategoryDto(categoryId=37, categoryName=中医科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=标准, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3335, appHits=38, showAppHits=0, pcHits=1007, showPcHits=3297, likes=0, shares=3, comments=3, approvalStatus=1, publishedTime=Tue Nov 30 10:02:15 CST 2021, publishedTimeString=2021-11-29, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 29 22:25:47 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 03:07:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_中成药临床综合评价技术规范.pdf)])
_中成药临床综合评价技术规范.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1083360, encodeId=d81d108336033, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:08 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083362, encodeId=a334108336202, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:11 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083361, encodeId=e9f9108336127, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:10 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 一己怀

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1083360, encodeId=d81d108336033, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:08 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083362, encodeId=a334108336202, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:11 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083361, encodeId=e9f9108336127, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:10 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 一己怀

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1083360, encodeId=d81d108336033, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:08 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083362, encodeId=a334108336202, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:11 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083361, encodeId=e9f9108336127, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:56:10 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 一己怀

    谢谢分享

    0